How Long Does Eloralintide Stay in Your System? What the Literature Reports

The short answer, and what it rests on

Eloralintide (development code LY3841136) was reported as a selective, long-acting amylin receptor agonist evaluated in a phase 1 proof-of-concept program for obesity (PMID 41559929), with a companion account tracing the molecule from discovery to clinical proof of concept (PMID 41109426). The word that does the pharmacokinetic work in those reports is long-acting. That descriptor tells readers the molecule was engineered for persistence measured in days rather than the minutes-to-hours range of native amylin, but it is not the same as a published half-life number, and this page does not supply a figure the verified sources do not state.

Because of that, the honest structure of an answer is two-tiered. Tier one is compound-specific: what the eloralintide papers themselves said. Tier two is general peptide pharmacokinetics — the elimination routes, the half-life arithmetic and the clearance modifiers that apply to engineered peptide therapeutics as a class. Every statement below is labelled as one or the other. For the class-level background, see how long peptides stay in your system; for the compound overview, see eloralintide.

What the eloralintide literature actually says (compound-specific)

The discovery-through-clinic report characterised eloralintide as a novel amylin receptor agonist developed for the treatment of obesity and carried through to clinical proof of concept (PMID 41109426). The phase 1 report described it as a selective, long-acting amylin receptor agonist assessed for proof of concept in humans (PMID 41559929). A pharmacology review placed the molecule in the wider context of amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs beyond GLP-1 agents (PMID 42586227).

Three things follow from that, and nothing more:

• Selectivity was a design claim. Researchers framed the molecule as acting at amylin receptors rather than as a mixed-receptor agent (PMID 41559929).
• Duration was a design claim. The long-acting label in the trial report (PMID 41559929) signals deliberate half-life extension relative to the native hormone.
• Human exposure data exist but are early. Phase 1 proof of concept means first-in-human pharmacology, not the multi-year, multi-population dataset that eventually fills a prescribing label (PMID 41109426).

Readers looking for a terminal half-life in hours should note that abstract-level summaries of these reports describe the pharmacology qualitatively. Where a number is not in the verified source, this page omits it rather than estimating one.

How peptide drugs are cleared (general pharmacology, not eloralintide-specific)

Nothing in this section is attributed to the eloralintide papers. It is standard peptide pharmacology, included so readers can interpret the term long-acting.

Elimination routes

Peptide therapeutics are generally handled by proteolysis — enzymatic breakdown into constituent amino acids by peptidases in plasma, interstitial tissue, liver and kidney — rather than by the cytochrome P450 oxidation pathways that dominate small-molecule metabolism. Smaller peptides are also filtered at the glomerulus and reabsorbed or degraded in the proximal tubule. The practical consequence is that the breakdown products of a peptide are ordinary amino acids and short fragments that merge into the body's own amino-acid pool, which is one reason peptides are difficult targets for conventional toxicology screening.

Why some peptides last days and others minutes

Native regulatory peptides are typically cleared within minutes. Medicinal chemists extend that using several well-described strategies: fatty-acid acylation that promotes reversible binding to circulating albumin, substitution of protease-susceptible amino acids, backbone modification, and formulation choices that slow absorption from a subcutaneous depot. When a molecule is described as long-acting, one or more of these approaches has usually been applied. Half-life extension built on albumin binding also means that plasma protein handling, not just kidney filtration, influences how quickly concentrations fall.

The washout arithmetic

Pharmacologists estimate clearance from the half-life using first-order decay: roughly 50% of circulating drug is gone after one half-life, 75% after two, about 94% after four and about 97% after five. The table below is a generic illustration of that arithmetic, not measured eloralintide data — it simply shows how much the assumed half-life changes the answer.

Two caveats matter. First, measurable drug and measurable effect are different endpoints: receptor-mediated effects can fade before plasma concentrations become undetectable, and in some systems downstream physiology outlasts the drug. Second, after repeated administration a drug accumulates to steady state over roughly four to five half-lives, so washout from steady state starts from a higher peak than washout from a single exposure.

Factors that change how long a peptide persists

These are class-level modifiers described in general pharmacokinetic practice; the eloralintide reports summarised above do not break exposure down by these variables in their abstract-level descriptions (PMID 41559929).

• Kidney function. Reduced glomerular filtration slows elimination of renally cleared peptides and fragments, raising exposure for a given amount administered.
• Liver and tissue peptidase activity. Proteolytic capacity varies with age, illness and nutritional status.
• Body size and composition. Volume of distribution scales with body mass, which alters peak concentration and the shape of the decay curve.
• Subcutaneous absorption. For depot-forming peptides, absorption can be slower than elimination, so the apparent half-life reflects how fast the drug leaves the injection site rather than how fast the body destroys it.
• Anti-drug antibodies. Immune responses to a peptide can either accelerate clearance or, by forming circulating complexes, prolong it. Immunogenicity assessment is a routine part of peptide development programs.
• Co-administered agents. Peptides are less prone to the CYP-mediated interactions that dominate small-molecule pharmacology, but agents that change gastric emptying, renal perfusion or plasma protein binding can still shift exposure.

Detectability and drug testing: what is and is not screened

This is the question behind most "how long does it stay in your system" searches, and the plain answer is that routine testing does not look for peptide drugs.

Workplace and clinical urine panels

Standard workplace panels — the familiar five- and ten-panel urine screens — are immunoassays targeted at drugs of abuse: amphetamines, cannabinoids, cocaine metabolites, opiates, phencyclidine, and in extended panels benzodiazepines, barbiturates, methadone, propoxyphene and MDMA. A peptide therapeutic is not an analyte on those panels, does not cross-react with those antibodies, and would not be reported by them. The same is true of routine pre-employment and insurance screens and of standard hospital toxicology.

What would detect a peptide

Identifying an intact peptide or its fragments requires a purpose-built method, typically liquid chromatography coupled to high-resolution or tandem mass spectrometry, or an immunoassay raised specifically against that molecule. Those assays are built inside drug development programs for pharmacokinetic sampling — the kind of bioanalysis that underpins a phase 1 report such as the eloralintide proof-of-concept study (PMID 41559929) — and in specialised anti-doping laboratories. They are not part of general medical or employment testing.

Sport and regulated competition

Anti-doping laboratories use targeted mass-spectrometry methods and periodically add new analytes as molecules enter clinical development. Whether any given investigational agent falls within a prohibited class, and what detection window applies, is determined by the current list published by the relevant governing body rather than by pharmacokinetics alone. Athletes subject to testing obtain that information from their anti-doping authority.

Disclosure to clinicians

Because no routine assay reports peptide exposure, a treating clinician learns about it only from the patient's history. That is a factual observation about assay coverage, not guidance.

Tolerability and Pharmacology: What Studies Report

The review of amylin-based pharmacotherapy framed the whole class around tolerability, positioning amylin receptor agonists within the search for better-tolerated weight-loss drugs beyond GLP-1 agents (PMID 42586227). Eloralintide was reported as a selective amylin receptor agonist carried to phase 1 proof of concept (PMID 41559929), with the preclinical-to-clinical narrative described in the discovery report (PMID 41109426). The study-level adverse-event tables, exposure–response relationships and numeric pharmacokinetic parameters sit in the full texts of those papers; this page does not reproduce figures that the verified abstract-level sources do not state. Readers who need event rates are directed to the primary publications themselves.

One pharmacological point is worth separating from clearance: amylin receptor agonism acts on satiety and gastric emptying pathways, and physiological effects of that kind do not necessarily track plasma concentration minute for minute. A drug can be largely eliminated while a downstream effect is still resolving, which is why "out of the system" is an ambiguous phrase unless the endpoint — measurable drug, measurable metabolite, or measurable effect — is specified.

What the literature has not settled

1. Published population pharmacokinetics. Early-phase reporting establishes proof of concept (PMID 41109426); broader modelling across body weight, renal function and age typically follows in later programs.
2. Special-population exposure. Renal and hepatic impairment studies are standard later-stage work and are not described in the verified sources here.
3. Long-term immunogenicity. Antibody development over extended exposure, and any effect on clearance, is a question for longer trials.
4. Comparative class pharmacokinetics. How amylin agonists line up against one another on duration was discussed at class level in the review (PMID 42586227) rather than resolved by head-to-head PK data.

Regulatory status in plain terms

Eloralintide appeared in the literature as an investigational compound in clinical development (PMID 41559929). Investigational agents are studied under regulated trial protocols; material supplied for laboratory work is labelled research-use-only and is not an approved medicine. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, including anything relating to investigational drugs, pharmacokinetics or drug testing.

References

• Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept (Molecular Metabolism, 2025)
• Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept (Diabetes, Obesity & Metabolism, 2026)
• Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs (Pharmacological Research, 2026)